BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

Impact · against what's priced in

The article provides no new material catalysts for BioNTech or Vertex Pharmaceuticals, as the reported financial losses and margin strengths are already reflected in their current valuations.

BNTX+0.00

Already priced in

The price assumes

the steep 60% drop in quarterly COVID-19 vaccine revenue... and the resulting net loss

The report of a $1.3 billion net loss for FY 2025 and TTM EPS of -$6.87 aligns with the market's current expectation of a COVID-19 revenue collapse.